A pilot, multicenter, open-label, one-group study to explore the efficacy, tolerability and safety of an oral once-daily 300mg dose of glatiramer acetate (GA) in subjects with Relapsing Remitting (R-R) Multiple Sclerosis (MS).

Authors
Category Primary study
Registry of TrialsEU Clinical Trials Register
Year 2004
This article has no abstract
Epistemonikos ID: 1479998d578bfd3198f49a66ae8921c2c223a930
First added on: Jan 21, 2025